United States Department of Commerce’s National Technical Information Service has named HWC a Joint Venture Partner

HWC | September 25, 2020

HWC announced today that the United States Department of Commerce’s National Technical Information Service (NTIS) has named HWC a Joint Venture Partner, bringing the firm’s innovation and expertise to solving complex data challenges across the federal government. As an NTIS Joint Venture Partner, HWC joins a select group of 32 leading organizations, including private-sector companies, academic institutions, and non-profits, who provide innovative data services to federal agencies to advance federal data priorities, promote economic growth, and enable operational excellence. This selection and recognition by NTIS further solidify HWC’s position as a leader in the digital and data services space and allows the company to provide cutting edge data solutions to a wide range of federal customers.

Spotlight

Cook County Board President Toni Preckwinkle today set in motion the development of a plan that will look at the County's transportation network and its impact on economic growth and quality of life over the next 25 years. "We can no longer continue to make one-off transportation investments. We need a coherent strategy. The County should invest in transportation as a way to foster economic development and create communities that are desirable places to live and work," Preckwinkle said. "With more than half of the metropolitan region's population, jobs and businesses, Cook County should be a leader in planning, prioritizing and aligning resources. We want to ensure Cook County's transportation investments are sensible, coordinated, and support growth." Called "Connecting Cook County," the Long Range Transportation Plan (LRTP) will be developed over the next 18 months. Cook County's last comprehensive transportation plan, now more than 70 years ago, identified the corridors for the today's Chicago-area expressway system. This LRTP is expected to set an agenda through 2040. Preckwinkle named a 17-member Advisory Committee composed of business leaders, along with representatives from civic groups, local governments, and economic development organizations, to give a broad voice to the various interests groups and their concerns. She also named a 15-member Program Committee of transportation professionals and specialists who will bring their specific areas of expertise to the table.

Spotlight

Cook County Board President Toni Preckwinkle today set in motion the development of a plan that will look at the County's transportation network and its impact on economic growth and quality of life over the next 25 years. "We can no longer continue to make one-off transportation investments. We need a coherent strategy. The County should invest in transportation as a way to foster economic development and create communities that are desirable places to live and work," Preckwinkle said. "With more than half of the metropolitan region's population, jobs and businesses, Cook County should be a leader in planning, prioritizing and aligning resources. We want to ensure Cook County's transportation investments are sensible, coordinated, and support growth." Called "Connecting Cook County," the Long Range Transportation Plan (LRTP) will be developed over the next 18 months. Cook County's last comprehensive transportation plan, now more than 70 years ago, identified the corridors for the today's Chicago-area expressway system. This LRTP is expected to set an agenda through 2040. Preckwinkle named a 17-member Advisory Committee composed of business leaders, along with representatives from civic groups, local governments, and economic development organizations, to give a broad voice to the various interests groups and their concerns. She also named a 15-member Program Committee of transportation professionals and specialists who will bring their specific areas of expertise to the table.

Related News

GOVERNMENT BUSINESS

LifeOmic's Precision Health Platform for Government Achieves FedRAMP Ready Status

LifeOmic | June 16, 2021

LifeOmic, the creator of the LIFE mobile apps, Precision Wellness, and the Precision Health Cloud platform, which are used at major medical and cancer centers, announced today that its Precision Health Platform for Government had achieved the Federal Risk and Authorization Management Program (FedRAMP) Ready status (PHP-G). PHP-G is a cloud and mobile platform that aggregates data for storage, analytics, and the development of predictive models. Today's healthcare IT systems do not democratize data, making research and discovery more difficult. The LifeOmic PHP-G cuts down these silos while drastically speeding a wide range of precision health and wellness use cases, including clinical trials and health research. LifeOmic can now provide its safe and endlessly scalable mobile-to-cloud solution to government agencies to combine multi-omics and clinical data, conduct research, engage in telehealth coaching, and expedite discovery due to FedRAMP Ready status. The LifeOmic PHP-G was designed by the same team that built one of Amazon Web Services' most complex cloud applications (AWS). It was developed as a cloud-first model, employing the most secure and scalable design principles, such as a zero-trust security model and serverless computing. Customers of LifeOmic can use the PHP-G to store, combine, and analyze data using any set of tools. The platform complies with HIPAA, is HITRUST CSF Certified, GDPR compliant, and CCPA compliant. FedRAMP is a US government-wide initiative that provides a consistent cloud security assessment, authorization, and continuous monitoring. FedRAMP compliance indicates that a cloud computing system has developed and documented a highly secure environment that has undergone a thorough and rigorous review. The FedRAMP Marketplace lists authorized cloud service providers. PHP-G is a few biomedical firms offering FedRAMP Ready mobile, biomedical informatics, data management, and machine learning solutions. About LifeOmic LifeOmic is a software company that uses the cloud, machine learning, and mobile devices to enable precise health and wellness solutions for employers, providers, researchers, healthcare IT, pharmaceutical companies, and people. The cloud-based software used by the company securely gathers, saves, and analyzes patient data to expedite the development and delivery of precision health treatments, disease management, and disease prevention. LifeOmic's enterprise product portfolio includes the Precision Health Cloud and Precision Health Platform for Government, both cloud and mobile-based sources for all patient data, including clinical data, whole genome sequences, gene expression levels, lab results, and medical images. Precision Wellness, a scientifically rigorous, employee-first corporate wellness solution, was also developed by the company. The LIFE Extend and LIFE Fasting Tracker mobile applications; the LIFE Apps health resources website; Lifeology, health literacy, and education platform; and SkillSpring, which links health coaches and medical professionals specialists with consumers the company's consumer products.

Read More

GOVERNMENT BUSINESS

Endo Announces Fill-Finish Manufacturing Agreement with U.S. Government to Support Production of Critical Medicines

Endo | November 20, 2021

Endo International plc today announced that its subsidiary, Par Sterile Products, LLC (Par Sterile), has entered into a cooperative agreement to expand its sterile fill-finish manufacturing production capacity and capabilities at its Rochester, Michigan plant to support the U.S. government's national defense efforts regarding production of critical medicines advancing pandemic preparation. Under the terms of the agreement, Par Sterile's Rochester facility will establish a new sterile fill-finish manufacturing asset capable of processing liquid or lyophilized products requiring Biosafety Level (BSL) 2 containment. It will also provide expanded product inspection and packaging capacity as well as sterile fill-finish manufacturing services to the U.S. Government. Under the terms of the agreement, the U.S. government will fund approximately $90 million of the program's total expected cost of approximately $120 million. "Endo strives to be a force for good, and we are proud to partner with the U.S. government in its efforts to expand and accelerate domestic manufacturing in support of future pandemic preparedness. This collaboration underscores our longstanding history as a U.S. manufacturer of high-quality medicines." Blaise Coleman, President and CEO of Endo The agreement is a result of efforts defined under the Defense Production Act to address vulnerabilities in critical product supply chains and strengthen the advancement of manufacturing and on-shoring of domestic essential medicines production. The Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) Joint Assisted Acquisition team in partnership with Army Contracting Command– Aberdeen Proving Ground (ACC - APG) – COVID Response are the awarding and administering acquisition offices. This work was supported by the ACC - APG – COVID Response, under the authority of 31 U.S.C. 6305 pursuant to Section 3101 of the American Rescue Plan Act (Public Law 117-2) and Title III of the Defense Production Act of 1950 (50 U.S.C. 4533) under Award No. W58P05-22-2-0001. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the JPEO-CBRND or ACC – APG – COVID Response. About Endo Endo is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them.

Read More

GOVERNMENT BUSINESS

MilliporeSigma Announces $136.7 Million U.S. Government Contract Award for New Lateral Flow Membrane Production Facility in Sheboygan, Wisconsin

MilliporeSigma | December 30, 2021

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has been awarded a $136.7M USD contract award for the construction of a lateral flow membrane production facility over a three-year period at the company's Sheboygan, Wisconsin site. The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness. "With this agreement, MilliporeSigma will construct a state-of-the-art lateral flow membrane production facility that will give our in vitro diagnostic (IVD) manufacturing customers greater flexibility and security of supply of our Hi-Flow™ Plus lateral flow membranes." Matthias Heinzel, Member of the Executive Board and CEO, Life Science, Merck KGaA, Darmstadt, Germany "Our lateral flow membranes have earned a reputation for high consistency among rapid diagnostic manufacturers and the already robust demand for this membrane has significantly increased since the onset of the pandemic. With this critical investment, we are expanding much-needed access to essential diagnostic testing as a trusted partner to the world's most sophisticated diagnostic manufacturers," said Jean-Charles Wirth, head of Applied Solutions, Life Science. Building this new facility supports the overall Life Science business sector's strategy to add physical capacity and expand its regional network to enable further growth of its key portfolios. Hi-Flow™ Plus Lateral flow membrane is used in rapid diagnostic test kit manufacturing by the Life Science business' customers, enabling reproducible results due to its consistent quality and optimized properties. The rapid test kits are used for a variety of applications, including Infectious Disease testing (Covid-19, HIV, Influenza, Malaria, etc.), as well as in women's health, biomarker detection, drug testing, food safety and animal health. Due to continuously increasing demand for lateral flow membrane, the Life Science business had already invested in a second membrane casting line in Cork, Ireland, which was recently completed, and expanded the range of other critical reagents (antibodies, beads, blockers, buffers) utilized to develop lateral flow rapid test kits. These strategic investments position the Life Science business as an important critical raw material supplier for the Diagnostic market, especially as the company prepares for IVD Regulation and Medical Device Regulation. The Life Science business is undertaking an ambitious, multi-year program to increase production capacity and capabilities to support the growing global demand for lifesaving vaccines, therapies and diagnostics. Within the last year, the company has accelerated investments to expand capacity to produce its support Mobius® single-use assemblies in both the U.S. and France, as well as increased capacity for the production of cell culture media in the U.S. and UK, among others. Additionally, several expansion projects continue to advance across the company's manufacturing and distribution global network. About the Life Science business of Merck KGaA, Darmstadt, Germany The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 23,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Read More